LVW Advisors LLC Has $211,000 Stake in Bristol Myers Squibb Company $BMY

LVW Advisors LLC cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,553 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. LVW Advisors LLC’s holdings in Bristol Myers Squibb were worth $211,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. TOWER TRUST & INVESTMENT Co boosted its stake in Bristol Myers Squibb by 2.7% during the second quarter. TOWER TRUST & INVESTMENT Co now owns 10,142 shares of the biopharmaceutical company’s stock worth $469,000 after acquiring an additional 270 shares in the last quarter. Diversified Enterprises LLC boosted its stake in Bristol Myers Squibb by 58.5% during the second quarter. Diversified Enterprises LLC now owns 8,037 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 2,966 shares in the last quarter. Brown Lisle Cummings Inc. boosted its stake in Bristol Myers Squibb by 13.5% during the second quarter. Brown Lisle Cummings Inc. now owns 19,000 shares of the biopharmaceutical company’s stock worth $880,000 after acquiring an additional 2,262 shares in the last quarter. Kendall Capital Management boosted its stake in Bristol Myers Squibb by 17.3% during the second quarter. Kendall Capital Management now owns 55,752 shares of the biopharmaceutical company’s stock worth $2,581,000 after acquiring an additional 8,210 shares in the last quarter. Finally, Cove Private Wealth LLC boosted its stake in Bristol Myers Squibb by 17.8% during the second quarter. Cove Private Wealth LLC now owns 13,365 shares of the biopharmaceutical company’s stock worth $619,000 after acquiring an additional 2,020 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.07% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $44.12 on Monday. The firm has a 50-day moving average of $46.63 and a 200-day moving average of $49.00. The company has a market cap of $89.80 billion, a P/E ratio of 17.79, a P/E/G ratio of 2.26 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Citigroup dropped their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.